Thanks for the advice Saxien , but I think I will leave my money...

Thanks for the advice Saxien , but I think I will leave my money right where it is . Trials due shortly for two different applications . The company have already stated they dont intend to take it all the way to market . Either of the two applications could be partnered out , and depending on the trial results one or both could be very valuable items . They also have the veterinary , diagnostic and palative care applications in the pipeline . The company has already stated that hey have met their endpoints for the phase 1 and have even announced significant tumour reductions amongst early patients (what is to come with data from later patients?) . They said at the shareholders meeting from memory that they were continuing the trial for more evaluation on how it boosts the immune system . Now it seems they have found a combination drug in Hybridons DNA oligoneucleotide (IMO) that potentiates Coramsines immune boost even further . The HRT was a good decision considering the bad press HRT was getting .
In my opinion this will be a very good year to hold Solbec . Cheers .